INO - Earnings call transcript Q1 2021 | Inovio Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Inovio Pharmaceuticals First Quarter 2021 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I'd now like to turn the conference over to Ben Matone, Senior Director of Investor Relations. Please go ahead.

Ben Matone

Operator. you, Thank joining call. for first XXXX quarter Thank the conference earnings you Inovio

Joining Joseph and and Chief are CEO; call President of Officer; me today's on Research Senior Mammen, Dr. Broderick, Laurent Chief Kies, Vice Senior Dr. Dr. President Anza Dr. Clinical Mr. CFO; Kim, Kate Jackie Development. Officer; Shea, Development; Operating of Humeau, Scientific Dr. Peter and President Vice

our XXXX. For quarter corporate we today's review and first XX, will for ended information March financial the call,

In discuss from regarding Innovate on well will forward addition, Phase trial the study. an X path provide as release we for press morning's this Phase our COVID-XX X update our data Company's as global the for

for equity analysts. remarks, research prepared will a we question reserved Following conducting be and segment answer

market. we based file All time the results integrated the We Factors statements Risk statements SEC, our that cause related clinical During compliance you materially. requirements, medicine, factors collaboration of the would the with to verbally to concluded. These will replay events under and could cost could the parties this forward-looking call readouts is and that, data the are partners, turn Including level Inovio's regulatory documents limitation, to available over performance to events activities Company I management which to and our ir.inovio.com conducting our on with today. on website be to matters. differ strategic and call of differ webcast in potentially like CEO, capital events will beliefs and expressed and or trials, the With uncertainties today. timing to the after results third to call heading Kim. refer and clinical relate This regulatory be products has materially from discovery along as resources without develop future Joseph business platform of a by time Inovio's applicable making future and to being these President developments we associated independent regarding live of and Company. and our expectations and Actual which made with bringing of actual development identify writing risks DNA important assist clinical shortly include of with the Dr. plans those from the business to call,

Joseph Kim

be been us Awaiting impact are holiday getting encouraged challenged to progress Thank to viral And you, you were for access in call. but and the of Ben. chain travel strains made the of to U.S., on that has around given we by Today, connected, for the world unclear in the cold to the spread much a that were how transport and and When world. arm continuing We mindful shots Navigating later, the emerging quarter of cold vaccine ultra variants. gatherings join the impact address we're time and the on and the still of struggling everyone variant outbreaks get place. emergence to in vaccines. different thank very rollout. logistics the of to facilitate by here taking last particularly we community to the today's a spread, is

April, United would implementing impact the is that on to a In global outside increasingly global that know to largely be we of infectious for As commitment unmet late community. announced recognize public we the Equally, our vaccine crisis health, we INO-XXXX. Phase X ability with States. needs and long-standing still a company roots in deep we have health public greatest this trial a disease the the

to with the start to this trial plan achieve working this and are expect We funders summer. partners and

within agreements of details to countries discussions are proceeding market in the countries Phase trial being this be planned. clinical continue number to look a with We these and with regarding INO-XXXX the initiate have we stated. forward we Segment where remain of previously this summer, our Additionally, will procurement regarding trial we additional sites track events efforts Phase to Innovate weeks. in X X on as to share Most have the importantly, coming

the who I'd announced Now, to results to Dr. Anza you us introduce to like Phase more we leading trial tell Anza? morning. X this Mammen our global is INO-XXXX X about Phase

Anza Mammen

adverse reported not of our included with INO-XXXX very and Phase advancement two of well to immunogenicity dose. second and XX The the Thank larger not results. in severity planned and grade dose result safe, the of at number nice that of the X all It The supports X Phase you increase Results common groups trial. with continues that adverse X Phase clinical high milligram T-cell immune and segment to further tolerability we efficacy ELISpot in statistically risk the events assay were at X pleased We dose immunogenicity peer controlled dosing groups. events placebo levels the binding group did pulled compared adults is Safety and the group. INO-XXXX, were appreciably trial. Phase vaccine of the measured responses milligram Likewise, SARS-CoV-X. and in differ regimen in A into grade doses the The of to most trial in in that be shortly INO-XXXX validating blinded either age X experiencing X/X in of of efficacy frequency and of Phase trial Joseph. ages of advancing immunogenic The preliminary a milligram results publication X of U.S. the across significantly in participants X X you, in a in have look be to XX sites to majority on between into paper geometric blinded very exposure. our preliminary trial, tolerability and each versatility the pre-print a the been dose did a milligram X-to-X our initial as this in safety, been the older report placebo. call milligram Broderick today. the X safety, Immunogenicity studied, rise against INO-XXXX morning, the milligram tolerated are adult the Innovate showed Phase the INO-XXXX receive population global a or randomization of X with XXX participants to X entitled, dose currently higher posted of placebo-controlled of a The greater versus the of X has segment namely review. X The randomized milligram also prior favor the mean planned were results group. potential dose, addressing will INO-XXXX the X X X variants. and Phase from published group you INO-XXXX the Dr. by the dose Phase share antibody dose neutralizing X circulating DNA clearly Again, dose

for favorable you, capabilities. planned As I SARS-CoV-X is segment. it leverage other variance profile the known in hinder Phase efficacy important X and and us continues against to its Joseph. INO-XXXX's vaccine It global while mitigate our turn back circulating to will to tolerability we that, evaluate safety evolve And potentially ability to with

Joseph Kim

of X on is will that also moment develop against take to of trial global we boosting Pan-COVID a plan increasing Senior announced parallel, Inovio want on now R&D, activity variant support both well to major detail second-generation to for INO-XXXX into I'll Vice in NextGen I Dr. we summer. our to efforts the the Broderick, variant Inovio's capabilities, a in Thanks, INOXXXX. as our vaccination vaccine data as make as us ask greater focused Pan-COVID prevalence Kate? Anza. primary track to as vaccine INO-XXXX. on variants Inovio's Kate Phase well update dual this variants. April, President all an need a INO-XXXX's of given strategy. speak to share about In a particularly recognize the We

Kate Broderick

UK variants. viral in the neutralizing April, those results neutralization recent The levels against all which a against from UK, variants African new protection will mRNA addition first then, as both Brazilian immunization these continues and against variants a the variants to protein collected activity during INO-XXXX spike variant, variants the the I providing the original variants against providing fully activity which vaccines. that SARS-CoV-X testing U.S.-based showing or time particular to key against when some tested, against reduced same, here Thank various strain. study original one a BXXX the were you the in against strains, neutralizing believes were induced the be the closely In to post or we vaccination the compared announced a by to new the responses previous vector approach currently African, X the by levels make variant those the you, in viral Wuhan and spike and INO-XXXX showed To variant variant. the capable Africa a mentioned in Company showed our SARS-CoV-X reduction analysis vaccines, call to Inovio's takeaways study. as caused the impact are BXXXX evolution tested, were the neutralizing UK, to activity. measured The responses INO-XXXX with in the variants of the levels mRNA INO-XXXX response the Company When I against the protein were focus Brazilian at trial. including generated that Clinical was reductions UK the the today. these of particular, reports Brazilian with emerging T-cell call, reports and strain. that Joseph, last that new T-cell South the streams antibodies and on earnings and antibodies of the and Inovio Company Africa crisis the Since Brazil. strain. by the vector South similar levels UK on against key The maintained hello spoke by Brazilian of were of induced the viral of comparable Brazilian South late shown were to the South by T-cell samples from neutralizing PX development INO-XXXX assessed in clinical Wuhan the two-pronged key Phase from mutations, the monitoring quarterly all everybody Despite robust to identified similar Wuhan points against and They variant subjects

study of cellular may provide reported this of important INO-XXXX encouraging variant T-cell together strains be the maintenance vaccinated protection humoral an for overview that the showing SARS-CoV-X against against cross-reactive variants Taken with and immune individuals results for data SARS-CoV-X. responses of the in activity,

both As is Joseph future dual support we because the endemic recognize taking to and need pandemic considerations. a noted, Inovio approach track

publication vaccine, and current potentially our against In in we future with Pan-COVID prepaid work more addition developing near look-forward upcoming variant of a turn are INO-XXXX, back to will We second-generation which late-stage our to protect call robust variants designed INO-XXXX, future. on I to including sharing also the to concern. And the over our progress on INO-XXXX, update an Joseph. that, is

Joseph Kim

Thank you, Kate.

quarter. Peter before a wanted update our Kies summary our you But financial will CFO, Next, for to other provide that, briefly important programs. clinical the on I

trial in immuno-oncology combination combination an The Sanofi, XX inhibitor by ongoing. is currently INO-XXXX newly treatment data later including the and immunology efforts, and for Phase jointly update the Regeneron which of being diagnosed of survival sharing First, Company year. is novel multiforme INO-XXXX this months potential data, correlated Inovio's Libtayo, developed and overall checkpoint X/X anticipates on tissue glioblastoma our PD-X in currently with

looks also months Phase at subjects one RNA and cervical technologies for for the safety the for to HSIL an The in-vitro caused of sharing HPV-XX primary administration, and following secondary efficacy guide REVEAL Inovio met we pivotal REVEAL decision-making follow cervical meeting. efforts, HSIL. durability disease Company the continuing treatment for HPV-related VGX-XXXX subjects to based our XX evaluable among announced endpoints As our with and findings clinical continues scientific QIAGEN for on trial this by trial of one, of diagnostic forward We're later the use partnership evaluating response last in and HPV-XX. year to and/or for treatment that all VGX-XXXX on sequencing a X our

who to commercial a setting respond our will to would Importantly, VGX-XXXX to likely immunotherapy. patients help this perspective us in be biomarker most identify

Phase in additional across regarding information continue any X REVEAL trial year. We'll Our later X XX global protocol efforts recruitment sites. adjustments the have this on

the evolve expand Following continues exploring our evaluate financial Phase Phase with X best the for and Inovio to X efficacy I path currently and our indications, the ways indications dysplasia clinical data, over FDA. Peter dysplasia. positive anal to discussions vulvar trial for also further anal would We're best VGX-XXXX to the to call that, summary. our Peter? With pending first for turn quarter

Peter Kies

$XXX.X financially cash, years we positioned $XXX.X capital the cash of We investments, Thanks, and quarter hello entered XXXX Thanks Joseph, proceeds short-term existing to equivalents January, million well successful with of investments $XXX.X We offering total and a in provided net with everyone. of short-term public and cash, multiple us and programs. cash first equivalents ended support sufficient million. activities with providing in to million.

financial quarterly our to now results. Turning

Our which million $XXX,XXX, revenue quarter compares for the to was XXXX. same first period for XXXX the in $X.X

Our $XX.X period million compared total to operating in were million, the XXXX. expenses $XX.X same for

share for the million or $X.XX ago. loss loss of basic quarter was the compares dilutive and and a or first net XXXX basic period for dilutive to $XX.X million $X.XX net per which Our per share $XX.X same a year

other an increase among well R&D Innovate programs million for developing were among expense, XPSP disease for XXXX, and to other quarter to trial million compensation, variances. contractor in COVID-XX, And limited engineering primarily period Joseph. for related back first non-cash services were related expense as which the our of trials. not $XX and progress period XPSP for of and increase infectious and $X.X planned increases Our our to compensation that, expenses quarter drug other $XX.X increase outside used increase be employee $XX.X you, expenses first INO-XXXX same manufacturing R&D million higher in and employee related was expenses legal stock-based The versus our INO-XXXX is expenses G&A services expenses, million same The to COVID-XX. were which the our it device, as selector the for I'll consulting the and with but the Also XXXX. R&D development compensation the for turn to primarily an G&A including in to variances. essential to for XXXX. including expenses many in in to clinical XXXX, and higher device, related compares These in continue

Joseph Kim

that good Thanks Inovio's Peter. It's to strong position. financial maintaining know

to and Before the funders thank tireless and we and recognize take team your questions,. their for I patients collaborators, would partners, Inovio like efforts. our

and and Our to COVID-XX vaccine safe effective evaluating vaccine and of commitment INO-XXXX against to team's support unwavering protect future of as concern. next INO-XXXX variants generation for in parallel Pan-COVID developing our while current

and validate technology oncology disease our broader infectious well impressive. to As continuing as and HPV is and platform within indeed

to confident Inovio, program's. If leave there is that from us, and still of DNA our one team's work advance platform While front Inovio's with am is more of in I one medicines can remain you in incredibly about today's highlight and this. ability proud point I call

to Phase We are staying support thank on this for remain continued track with our INO-XXXX development for plans temperature many and in summer. expect X committed and to vaccines. tolerable your effective, still you people stable INO-XXXX need safe, Inovio. for I commence developing of globally We desperate

open now call will the for questions, your We operator?

Operator

Geoff Please Meacham of Our America. Instructions] [Operator question first from from comes go Bank ahead.

Aspen Mori

for on just from Aspen taking for questions, It's Geoff. us. our Thanks a couple

development the the we OUS. how medical could Phase then to the primarily upcoming plays X now And you. additional run data Firstly, given VGX-XXXX, that study X? that plans current for how to about your clinical study, into talk we X at with REVEAL X conference Thank for expect what Phase an respect expect can Phase to see maybe you hold that

Joseph Kim

patient X level, Yes, so year follow efficacy REVEAL safety a to second the take this finish for expected will comprehensive data. full first. let is we me have that unblinded question safety so The up and later

later So that's this expect to year. would what have we

in global open not the X U.S., In absolutely Phase submit partial terms trial, Phase track the on of the partial not impacted X is and to for FDA INNOVATE partial on hold and along but with quarter. The plan hold to of X countries strategy clinical FDA we in sites We still are to plan U.S. the current recruit to ex-U.S successful Aspen ex- by the Phase to right. submission second clinical still all does if clinical hold, our - our trial. mostly lift INNOVATE the we're you're

me track you clinical of X you. as hopeful But U.S. of hold U.S. ex- submit will globally. able be come to for trials lift X most we Let the countries our trial. and suggested, are to reiterate, Phase patients from we will INNOVATE Phase Thank we're our our partial in the that on portion clinical

Operator

question Singh from go Oppenheimer. next ahead. The comes Hartaj Please from

Hartaj Singh

picked submitting one question, for And have just you terms to do lastly, Joe the the to up from have Joe, that's just that Inovio if dose update guess that renewing Phase Thanks are then to year. team. how blurb you authorities? terms update, explain J&J discussions updates? to you for milligrams to for your those revised submit authorities, that. sites to Thank talk the not And relevant the what the European protocol Union, specifically and on this follow protocols terms just are with for response as there protocol Aside later literature? filing clinical a in Number How that the hold, does X you. - can can your the of So that of news identifying what the now what the steps you've or your X impact just Norway, now protocol forward? to FDA? was today two, be last you in work going AstraZeneca clinical going worldwide, or that is you you of I the thinking to does contracts do going update regulatory your clinical is have in

Joseph Kim

will general thank of last But take further stab to of the again questions. last ask Yes, at address I question I'll all, part - first the first. and questions these you, Mammen Hartaj. your Dr.

landscape. the a availabilities and vaccine of changing renewal. I think the orders whole landscape That's

for a global that's X% COVID-XX So month far. One There sure. changing. of to vaccine every population is or be received seems thus only is every thing week the

a the demand is an unmet opportunities there against globally have pandemic. combat INO-XXXX to to in role play So our huge potential important and this

team, and partners, funders as to make get sure that soon possible. as can drives really So, there that our us our our we

drafting these so In the begun our terms a preparations filings submissions. already submitting lot of of right. all absolutely on, We've you're and and of for global

that each with weeks. of are global submissions. X countries have include into we'll our working our team efficacy each file for regulatory that But of CRO, we closely along the been to trial, prepare CRO, those to for So many our Phase internal very independent

would so like months, do the or any questions we're So, that Anza, to address any of to Hartaj's I a you position in great think in detail?

Anza Mammen

you, very working a absolutely. Thank Yes, with Joseph, we're CRO. experienced

So it's working on U.S. we've study countries X CRO been country that the experience. same Phase CRO ex- that included it's selection the - criteria our and for which and has our

that in of other in country as has with criteria are Inovio well had products, Another experience the a selection, of terms we've which at platform looked those countries as device.

- we quickly. us made allows country we've feel that selection move So confident is to that a relatively

the submissions. Now dose the be has CRO working protocol X regulatory and in amendment with through milligram prepare will to gone the our fact

are wanted I so points raise. those the to additional And

Operator

from ahead. go The from Markets. comes Capital next Please Renza question Gregory RBC

Gregory Renza

you taking discontinuation respect Joseph that my in team. and and funding just for of question Hi, DoD today. the Thank trial. to the with Phase also X the Joseph, - for for updates

about to the what program or just resource your your you has could little the resources I'm and how if discussion for who Just curious firstly pipeline. evolve? program just providing platform development impacts those you on curious should and funders expect should Thank think could U.S. you ex- just allocation cash that that that strategy evolved secondly, How you. And and around how elaborate provide just the to and the how then expect if I'm trial. pivoting we curious just in vaccine perception will potentially. partners And we comment on perhaps those had just and mentioned you that, related further your a across funds of

Joseph Kim

funding they Yes for unblinded group in X weeks, been had the Phase our our from us or a before pivot decision. immunogenicity Thanks, and obviously surprise. made decision see with many They that level trials Greg. they DoD didn't ex-U.S - Well, working certainly safety had our came

disclosed with or as not the they the not environment is data. COVID-XX really decision So of to do so investment their and anything decision we XXXX mostly our on us, informed which and much changing U.S., in -

preparations. we So data, and in feel in our comfortable our program, our in very confident

and been the X the funding Phase thank for - we continue prep for DoD I many have work So months Phase to and of the that doing X now. all

trial. but this that a execute details, give trial. is And mentioned, Anza prep currently to help expediently partners global into move working As going work can't X us us to with allow and to funders to potential we're we Phase any

what of I reduces U.S. from say Now, the the pivot to cost ex- it can is overall U.S., trial. generally

that's think So as also well. I helpful

for Anza we're some of moving spoke ex- to U.S. about. conditions looking obviously not Now cost we're that reasons, the for

at - those case Inovio randomized expertise, those there number significant trial. still in vaccines and of where emergency looking countries we're experience and are cases a areas CRO's Our placebo in do there control but where less driven are for also experience our efficacy a where I countries we can available and regions

So when the these triangulate important regions world are plans. conditions, there and that around into calculus fits very these you

should So, stay-tuned our more a Phase that the to X weeks. we details have few next trial, lot in disclosed about have

Operator

comes Stifel. from The Stephen Please from go ahead. question next Willey

Ellen Sands

Steve. kind placebo-controlled for of wondering is just question then Thank have severe study. able just X to up. having follow shortage one some interested arm targeting sort you. just for following actually or globe conversations I of an about and This vaccines regulatory across Thanks agencies vaccine Ellen run considered I data. know that would with study study. considering on you But previous in you're are are a the And if active a the is where there comparator are seeing be taking there doing if that approved the non-inferiority question. with is therefore This just countries Phase wondering the up and

Joseph Kim

way most we study still great options a question. our get to question feel efficacy Yes, that's placebo driven vaccine. the different that expedient case we have and for is And to our controlled those internally a considered

So, the pursuing we're that now. path that's

the trial the Of wide is quarters, still last over been landscape opportunity us the think case changing that is has course to I efficacy see. and several for but U.S. window driven there the open outside

Ellen Sands

great. you. then still this And disclose to in data for Thank RP intend Okay, INO-XXXX preliminary you year? do

Joseph Kim

and great likely is very our an question. that's a that's us. XXXX last received important have likewise RP drug Well, product label - disease a for INO-XXXX us, RP important for remains for X/X ongoing. the target and trial Phase for year open that's orphan We designation we

the impactful hopeful So going amount event, but data mid-XXXX level most still likely most of But data to it's of will be a later we're early year. to there's maybe meaningful this event. XXXX likely that be

Operator

question go comes Benchmark. next ahead. Aydin Huseynov from The Please from

Aydin Huseynov

my I the for Thanks taking with congratulations and question have… data.

Joseph Kim

Thanks, Aydin.

Aydin Huseynov

the we was the role geometric what's several In could on kinds opinion the neutralizing increase pre-publication. the of the binding higher on in antibody COVID-XX? you the - antibodies antibodies the data cold the geometric antibodies neutralizing titers titers> unit fold And on saw that of binding the overall, and your comment binding in than So in the antibody in against increase the

Joseph Kim

question. I is good think important a this question, very

platforms. protection. vaccine's very both that vaccines, titers, Especially So be to various Binding related response. aspects and neutralizing that antibodies of responses are antibody measurement, responses seems are was also immune potentially to the important a the of approved that measurement early some were the protection consistent antibody across even neutralizing important more emergency of important immune

we the those titers thirdly, the and important of those And providing also antibody protection. and impact strong of maintain and antibody arm very immune the in are important. both measuring those a system, believe we rise vaccine also of T-cell second the that belief is the increasing arm, levels feel we So and

to responses very in pleased Broderick generate UK. testing were variants Brazil South various Africa, our some see the whether like Phase we're Wuhan were that X So maintain looking are our the as the newer variants we to in we see very trials. or remarks, or strain Kate we excited at T-cell also of T-cell able mentioned were strong against of that responses And her overall to that major we concern when

Phase planning antibodies INO-XXXX start protection we we're is to our aspects one-two in for to that So and with this think important summer. having an punch be going efficacy trial the of providing in later T-cells X

Aydin Huseynov

Appreciate Thank question you, Joseph. have. one I And more that.

for of Regarding de the terms the or of other opportunity in INO-XXXX novo use. boosting INO-XXXX vaccine long-term or the

So what long you where mid-term the vaccine? for term not the do the opportunity see the,

Joseph Kim

- well, that key many that boosting regimen health COVID-XX to that a is regime think feel of boosting if to and experts, global experts are annual And abroad, the health correct, - and - here both seasonal having we they vaccination going follow. Yes, be potentially a over with seasonally is because think problems year-out having and the can year-in and be tolerably, will again, be safely vaccine endemic we stage boosted that the after of over certainly deal - changing and pandemic, with the important. COVID to variants very

as primarily vaccines being of potential vaccinated boost So we booster own potentially vaccine XXXX even Pan-COVID a be also And used Kate time. people other our first over that remarks vaccine variant generation both also long see is generation vaccinated a her think - a vaccine, a as in the or believe to as I INO-XXXX potential. also vaccine as can a having we mentioned INO-XXXX that that vaccine boosted the that but as next strong to primary a

AE So one amount great other feel-- DNA we XXXX limited and can in and a over-and-over of and DNA the in attributes our the platform Inovio's is anti-vector with INO key vaccines no be tolerability, of of portfolio have we boosted in data our of particular our response. profile vaccines that vaccines and significant

these come. to So INO-XXXX as subsequently INO-XXXX potential years and attributes great really I our vaccines boosters, then of say hopefully and think provide for our outlook potential for many

Operator

from comes next go Please Yi The ahead. Instructions] Wainwright. question from [Operator Chen H.C.

Yi Chen

- question. how and X Thank allocate much raise of you trial, Phase taking need the in a whether you Inovio bit your cash you tell external existing COVID-XX position plans to certain Could to my about amount complete would for to us global trial?. to from parties

Joseph Kim

that for question. Thanks

definitely - and very much in have our one to want now. we $X.X As But over we also maintain that's strengths billion possible. in the We the as strong remarks, as that Peter cash expense point. cash as want this at we summarized look to limit our a of and in at - right we

are and to funders ongoing the and few is next working and that the best with our weeks. So we X Phase be discuss that publicly we to currently in ready trials, to partners now how work hope conduct

funders this a as will the just lead originally our will confident extremely that where to happen the and of this be today So are global the to regions X make done, Places for I'm world. later. in hard very and are in - partners, was many that where effort feel our COVID-XX Inovio vaccines optimistic trial planned not team, our working of and INNOVATE U.S. needed able countries this truly we and but Phase

So to strategies looking weeks. forward articulated and details all next fully really in of the our having few we're

Operator

The next question comes from Sandler. ahead. Please Piper from go Chris Raymond

Chris Raymond

for the this the me also you respect so ask It comp I'll comment - neutralizing response, for on you address and what letting the gives forward recruitment? you. a like or response, don't just anybody Can I question. antibody in this. on a guys Thanks I've ask you think convalescent immune moving heard subjects I with ask, the from plasma? fair looks pretty there's reaction Thank the comparison investigators to in to sizable confidence to different guess

Joseph Kim

Yes. Thanks, Chris.

our which the all level we were met archive all from have. So, subject to yes, able compared samples group we that this pre-publication lays of XXX convalescent in some unblinding also to acquire. out the morning, of titer, data of we but the at Both really geometric the that mean the presented

particular saw against after the two X from zero, we dose level weeks and for group was baseline but the subjects group weeks, in their six really which neutralizing titers, antibody to second milligram milligram both good dose So X X compared feel we of at these in as placebo week at about the groups. our also milligram

trial in - better see qualitatively we X. the very So this confidence level the to can Phase that the Phase even we of strong and seem the GMP titers say neutralizing X intervals compared as is and

at is Now spread milligram the GMT wider higher we're the than generated. immune responses dose our is convalescent the But and also group. looking X

of our T-cells against neutralizing trial where a efficacy randomized, cases the global protection feel INO-XXXX can antibodies a COVID-XX in antibodies in terms trial. a in As I earlier, placebo-controlled in binding holistic mentioned way, controlled, provide that we and

this this promising can as So we trial look soon to Phase into a global taking vaccine we as summer. forward X

Operator

queue. more over question-and-answer would This for like turn no the back to concludes in questions I conference Kim are session. our the Joseph closing remarks. There any to

Joseph Kim

some Thank look VGX you, of you XXXX Thank well INO-XXXX forward as the and Phase presentation. trials our next the for few forward moving questions. and in XXXX, for insights Thanks to of to of forward later as listening the Yes, insightful We to we X INO-XXXX sharing look XXXX all everyone. weeks.

again So attention. thank for quarterly and you great this Have your night. for a call

Operator

attending you Thank The now concluded. conference presentation. today's for has

disconnect. may You now

Inovio Pharmaceuticals (INO) 10 May 212021 Q1 Earnings call transcript